To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.